Cardior Pharmaceuticals GmbH
https://www.cardior.de/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cardior Pharmaceuticals GmbH
Finance Watch: Venture Capital, Debt Financings Led Fundraising Surge In Q2
New VC deals include a $60m series C-1 round for DiCE Molecules a day before it filed paperwork to support a $100m IPO and a $100m financing for China’s IONOVA Life Science. Also, RenovoRx was the 84th company to go public in the US this year and ADC Therapeutics executed a $325m royalty deal.
Cardior Counts On RNA To Tackle Cardiac Disease
The German firm intends to use the proceeds from an over-subscribed round to move its micro-RNA-132 inhibitor forward into trials for heart failure and advance its pipeline.
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cardior Pharmaceuticals GmbH
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice